Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E)

PURPOSE: Papillary thyroid carcinoma (PTC) is the most frequent endocrine tumor. BRAF(V600E) represents the PTC hallmark and is targeted with selective inhibitors (e.g. vemurafenib). Although there have been promising results in clinical trials using these inhibitors, most patients develop resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonello, Zeus A., Hsu, Nancy, Bhasin, Manoj, Roti, Giovanni, Joshi, Mukta, Van Hummelen, Paul, Ye, Emily, Lo, Agnes S., Karumanchi, S. Ananth, Bryke, Christine R., Nucera, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689570/
https://www.ncbi.nlm.nih.gov/pubmed/29156680
http://dx.doi.org/10.18632/oncotarget.21262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689570/
https://www.ncbi.nlm.nih.gov/pubmed/29156680
http://dx.doi.org/10.18632/oncotarget.21262

Ejemplares similares